Phase 3 Recruiting NIH
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06337318
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
+ 285 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Locations: - University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
+ 239 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Providence Alaska Medical Center — Anchorage, Alaska
+ 200 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Locations: - Saint Joseph's Hospital and Medical Center — Phoenix, Arizona
- Kaiser Permanente-Anaheim — Anaheim, California
- AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
+ 174 more sites in the U.S.
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Locations: - Research Site — Huntsville, Alabama
- Research Site — Anchorage, Alaska
- Research Site — Phoenix, Arizona
+ 60 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Locations: - University of Alabama At Birmingham Hospital — Birmingham, Alabama
- Mayo Clinic Phoenix — Phoenix, Arizona
- Kaiser Permanente Southern California — Irvine, California
+ 46 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…
Sponsor: University of Rochester
NCT ID: NCT05006482
Locations: - Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente-San Francisco — San Francisco, California
+ 42 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Locations: - University of Alabama At Birmingham Hospital — Birmingham, Alabama
- University of Arizona Cancer Center — Tucson, Arizona
- Ucsf Fresno — Fresno, California
+ 38 more sites in the U.S.
Phase 3 Recruiting Industry
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Honor Health — Scottsdale, Arizona
- Mayo Clinic Arizona — Scottsdale, Arizona
+ 38 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Locations: - Uci Health Laguna Hills — Laguna Hills, California
- Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute — Palo Alto, California
+ 36 more sites in the U.S.
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Locations: - Local Institution - 0225 — Birmingham, Alabama
- Infirmary Cancer Care — Mobile, Alabama
- Alaska Oncology and Hematology — Anchorage, Alaska
+ 28 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lympho…
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT07104032
Locations: - Mayo Clinic Cancer Center — Phoenix, Arizona
- HonorHealth Cancer Center — Scottsdale, Arizona
- Providence Medical Foundation — Fullerton, California
+ 23 more sites in the U.S.